Revisiting Healthcare Resource Allocation for Immunotherapeutic Treatments in Cancer

H. MAHDIANI


Institute for History, Philosophy and Ethics of Medicine, University Medical Centre Johannes-Gutenberg University, Mainz, Germany. Am Pulverturm 13, 55131 Mainz, Rhineland Palatinate, Germany

INTRODUCTION

Onco-exceptionalism: Cancer is perceived and treated differently from other medical conditions, often resulting in unique considerations [1] in:

METHOD

- A scoping review
- Narratvie review of Principles of 4P Medicine





Development

• Both Government and Industry [2]

Approval	 Special Regulatory Pathways [3]
Reimbursement	 Priority setting criterias [4]
Pricing	 No clear association between drug prices and benefits [5]

Equity (the absence of systematic disparities in health or in the major social determinants of health) [6] – and operationalized through considerations into CEA.

- > Fair innings
- > Prospective Health
- Proportional shortfall

OBJECTIVE

relatively Since small а proportion of cancer patients have specific markers for which targeted therapies have been proven effective, (only 5% of over 500 tested cancer patients eligible for such were treatments)

Q: reimbursing highly costly drugs aligns with principles of equity?

Pearson TA, et al. JACC Adv. 2024;3(1):100759.


implementation ntervention

sciences Qualitative

RESULTS

Advancements in medical technology and precision medicine continue to unveil new biomarkers and interventions for cancer, attention must also be directed towards addressing *modifiable risk factors* such as obesity and smoking.

tionalism



Failure to do so may lead to a continued reliance on **O4***medicine* practices, which are characterized by "overtesting, overdiagnosis, overtreatment, [and] overcharging" [7].


for Onco

Arguments **Against** Onco-Exceptionalism: Based on 4P Medicine

Preventive	Predictive	Participatory	Personalized
 Shifting the paradigm from a 'reactive' to a 'proactive' approach In non-genetic cases: life style modifications e.g., Obesity, Smoking, Alcohol, Health literacy 	 Leroy Hood's concept of "actionable possibilities" Epidemiological knowledge-base 	 An opportunity and a right for the scientific citizen-patient Psychosocial factors 	Prevention through participation can make prediction and precision possible

CONCLUSIONS

(Role of citizen-patients) the responsibility of



REFERENCES

[1] Fu M, Naci H, Booth CM, Gyawali B, Cosgrove A, Toh S, u. a. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med. 1. Dezember 2021;181(12):1596.

[2] Weiner, Janet (2017): Precision Medicine Meets Cancer Exceptionalism. Is cancer special? Online verfügbar unter

- the individual against their own health- in prevention, prediction and precision.
- \succ (Role of governing agents) demanding transparency regarding R&D costs and end product cost
- \succ The need for a transition from merely treating illness to supporting the healthy in maintaining their well-being.
- > Too strong a focus on genomics in contrast to behavioral, environmental and social determinants of health [8].

https://silverberry.health/blog/5-pillars-of-precision-health

https://ldi.upenn.edu/our-work/research-updates/precision-medicine-meets-cancer-exceptionalism/, zuletzt geprüft am 30.07.2024

[3] Cowling et al 2023. JOURNAL OF MEDICAL ECONOMICS 2023, VOL. 26, NO. 1, 944–953 https://doi.org/10.1080/13696998.2023.2237336

[4] Vokinger et ak. 2017. Lancet Oncol 2020; 21: 664–70

[5] Culyer AJ. Ethics, priorities and cancer. J Cancer Policy. März 2017;11:6–11.

[6] Braveman P. Defining equity in health. J Epidemiol Community Health. 1. April 2003;57(4):254-8.

[7] Fiala C, Taher J, Diamandis EP. P4 Medicine or O4 Medicine? Hippocrates Provides the Answer. J Appl Lab Med. 1. Juli 2019;4(1):108–19.

[8] Ramaswami R, Bayer R, Galea S. Precision Medicine from a Public Health Perspective. Annu Rev Public Health. 1. April 2018;39:153-68.

[9] Pearson TA, Vitalis D, Pratt C, Campo R, Armoundas AA, Au D, Beech B, Brazhnik O, Chute CG, Davidson KW, Diez-Roux AV, Fine LJ, Gabriel D, Groenveld P, Hall J, Hamilton AB, Hu H, Ji H, Kind A, Kraus WE, Krumholz H, Mensah GA, Merchant RM, Mozaffarian D, Murray DM, Neumark-Sztainer D, Petersen M, Goff D. The Science of Precision Prevention: Research Opportunities and Clinical Applications to Reduce Cardiovascular Health Disparities. JACC Adv. 2024 Jan;3(1):100759. doi: 10.1016/j.jacadv.2023.100759. Epub 2023 Dec 13. PMID: 38375059; PMCID: PMC10876066.

